Lmr Partners LLP Inhibrx, Inc. Transaction History

Lmr Partners LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$32.76 - $39.56 $163,800 - $197,800	-5,000 Reduced 34.58%	9,458 $330,000
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $123,182 - $365,209	14,458 New	14,458 $164,000
Q1 2022 May 16, 2022	SELL	$19.89 - $43.18 $497,250 - $1.08 Million	-25,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $668,750 - $1.15 Million	25,000 New	25,000 $1.09 Million

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.